110results about "Chlorine active ingredients" patented technology

Provided is a method for producing a chlorous acid water preparation in which chlorous acid water, chlorous acid as a main effective component thereof, and chlorine peroxide radicals as active molecular species thereof have been more efficiently stabilized in the liquid at ordinary temperature in high and low concentrations. The method is for producing a chlorous acid water preparation having a predetermined content (in terms of chlorous acid (HClO2=68.46)), and comprises: (1) preparing a buffer solution; (2) obtaining the concentration of the buffer solution; (3) preparing chlorous acid water; (4) obtaining a content in the chlorous acid water (in terms of chlorous acid (HClO2=68.46)); (5) obtaining an amount of the buffer solution required for dilution, from the content in the chlorous acid water (in terms of chlorous acid (HClO2=68.46)) and the predetermined content (in terms of chlorous acid (HClO2=68.46)); and (6) diluting the chlorous acid water with said amount of the buffer solution to produce a chlorous acid water preparation having the predetermined content (in terms of chlorous acid (HClO2=68.46)).

Disclosed in the present invention are a pharmaceutical chlorine dioxide antimicrobial liquid agent, a preparation method therefor, and use thereof. The pharmaceutical chlorine dioxide antimicrobial liquid agent comprises: a solvent and chlorine dioxide gas infused into the solvent, wherein the concentration of chlorine dioxide in the pharmaceutical chlorine dioxide antimicrobial liquid agent is 5000 mg / L-10000 mg / L. According to the pharmaceutical chlorine dioxide antimicrobial liquid agent, the preparation method therefor, and the use thereof provided by the present invention, the obtained pharmaceutical chlorine dioxide antimicrobial liquid agent has high concentration, good stability, and high purity, meeting the requirements for the use of the pharmaceutical chlorine dioxide antimicrobial liquid agent as a pharmaceutical product.

The invention belongs to the technical field of biochemistry and medicine, and particularly relates to skin gel containing chemically modified lysozyme as well as a preparation method and application of the skin gel. According to the invention, chlorine dioxide is combined with the lysozyme in a chemical chelation manner, so that the antibacterial activity and stability of the modified lysozyme can be effectively improved. Through the innovative technical scheme, the chlorine dioxide chelate and the lysozyme can be effectively combined, so that the chlorine dioxide chelate and the lysozyme play a synergistic role to effectively enhance the antibacterial property of the modified lysozyme and improve the stability of the lysozyme in different environments, the defects in the traditional lysozyme application are effectively overcome, and the application potential of the lysozyme is improved; meanwhile, a new field is opened up for efficient application of chlorine dioxide.

Provided are anti-microbial compositions that include an aqueous solution of hypochlorous acid encapsulated in a nanoparticle that allows for controlled release of hypochlorous acid. Also provided are methods of making and using such compositions.

The present specification discloses a method of making a composition stably comprising one or more peroxides and one or more free available chlorine species, one or more peroxide for use in the manufacture of a composition stably comprising one or more peroxides and one or more free available chlorine species, as well as formulated compositions using a composition manufactured according to a method or use disclosed herein.

The invention discloses blood filtration replacement liquid as well as a preparation method and application thereof. The displacement liquid comprises low molecular weight heparin calcium, prostaglandin E1, prostacyclin, electrolyte with specific concentration, glucose and an interleukin-1 receptor antagonist. The preparation method comprises the following steps: weighing the raw materials according to the proportion, dissolving to a constant volume, removing pyrogen and heat, and carrying out aseptic packaging. During clinical application, replacement liquid and blood are filtered according to the replacement rate of 1: 1-2: 1 according to the condition of a patient, 4-6 hours each time and 2-3 times each week, and related indexes are monitored. Animal tests show that the replacement liquid has good safety under the effective dosage, and has potential influence on part of organs under the high dosage. A stability test shows that the compound can be stably stored under a certain condition. The invention provides the replacement liquid which can achieve anticoagulation and blood vessel protection, maintain electrolyte balance and relieve inflammatory response, is expected to improve the prognosis of hemodialysis patients, and has important clinical significance and wide application prospects.

Disclosed herein are methods for making compositions stably comprising one or more peroxides and one or more free available chlorine species, one or more peroxides for use in making compositions stably comprising one or more peroxides and one or more free available chlorine species, and compositions formulated using compositions made according to the methods or uses disclosed herein.

The present invention relates to the technical field of veterinary medicine, and specifically discloses a composition for treating cow mastitis and a preparation method thereof. The composition includes: 0.5 part-2 parts of a composite sodium chlorite effervescent tablet, 1.2 parts-1.5 parts of puerarin, 1.8 parts-2.0 parts of a chitosan-derived quaternary ammonium salt, 1 part-5 parts of modified nano zinc oxide, 2 parts-6 parts of magnesium-aluminum hydrotalcite, 1.6 parts-3 parts of an antibacterial agent, 5 parts-10 parts of a film former, 2 parts-4 parts of a plasticizer, 3 parts-7 parts of a surfactant, 1 part-2 parts of a thickener, and 550 parts-650 parts of distilled water. The composition provided by the present invention can fundamentally treat and prevent cow mastitis under the synergistic effect of each component, with a cure rate of more than 90%, and will not cause drug residues, thereby avoiding the generation of drug residues and bacterial resistance problems in cow's milk. The composition is suitable for promotion in animal husbandry and has broad application prospects.

This invention relates to the field of biomedicine and hygiene disinfection products technology, and discloses a method for preparing a slightly acidic oxidizing potential hydrogel. The gel is made from slightly acidic oxidizing potential water and an inorganic gelling agent, lithium magnesium silicate. The preparation method includes: separately preparing strongly acidic oxidizing potential water and alkaline reducing potential water by electrolysis; mixing the two online in a preset ratio; adjusting the pH value to 5.0 to 6.5 through a neutralization reaction; subsequently adding lithium magnesium silicate; and then dispersing the mixture through high-speed shearing and sealing for static swelling to form a gel. This invention solves the problems of easy decomposition of available chlorine and gel liquefaction by utilizing an inorganic gel system, resulting in a gel with high stability and a long shelf life. This product solves the problem of easy loss of liquid disinfectants, prolongs the bactericidal effect time on wounds and oral ulcers, and is non-irritating and non-sensitizing to the skin, making it suitable for long-term disinfection of hands, skin, and mucous membranes.

To provide a coronavirus killing agent.SOLUTION: The present disclosure provides coronavirus killing agents. In particular, the present disclosure provides a coronavirus disinfectant comprising a chlorous acid aqueous solution. In particular, the present disclosure provides a method for killing or disinfecting coronavirus using a chlorous acid aqueous solution. The concentration of free chlorine (assuming Cl = 35.45) in a chlorous acid aqueous solution can be at least 5ppm or higher in the absence of organic matter. The content of chlorous acid in the chlorous acid aqueous solution (HClO2 = 68.46) can be at least 200ppm or more under the presence of organic matter including disinfection of hands and the like. The coronavirus may be SARS coronavirus (SARS-CoV), MERS coronavirus (MERS-CoV), or 2019 novel coronavirus (SARS-CoV-2).SELECTED DRAWING: None

To provide a disinfectant composition that provides excellent cleaning and disinfection of medical devices.SOLUTION: A disinfectant composition comprising hypochlorous acid in an amount of at least 725 ppm and up to 1,200 ppm, or free available chlorine in an amount of at least 725 ppm and up to 1,200 ppm, and 2-1) one or more metal oxide particles present in an amount of 10 ppm to 300 ppm, the one or more metal oxide particles including copper, iron, titanium, zinc, or a mixture thereof; or 2-2) one or more metal oxide salts present in an amount of 10 ppm to 300 ppm, the one or more metal oxide salts including a metal acetate, a metal chloride, or a metal nitrate, the one or more metal oxide salts including a salt of copper and a salt of zinc.SELECTED DRAWING: None

A wound irrigation system includes a first fluid including an ion rich compound having free available ions; and a second fluid including an oxidation-reduction potential increasing compound, the second fluid housed separately from the first fluid. Mixing the first and second fluids in a charging area forms an ionically charged fluid with an oxidation-reduction potential higher than a wound site oxidation-potential. The ionically charged fluid increases antimicrobial activity of the wound upon application.

Provided are anti-microbial compositions that include an aqueous solution of hypochlorous acid encapsulated in a nanoparticle that allows for controlled release of hypochlorous acid. Also provided are methods of making and using such compositions.

A method of monitoring and treating a subject with ALS based on biomarkers. In some embodiments, the method comprises: identifying that a subject has a ratio of LPS1EGF associated with ALS; and based on the identifying that the subject has the ratio of LPS:EGF associated with ALS, determining that the subject is eligible for sodium chlorite therapy for the ALS, determining based on the ratio of LPS:EGF whether to continue the therapeutic regimen of sodium chlorite; wherein the ratio of LPS:EGF in the subject is no greater than 50 and the therapeutic regimen of sodium chlorite is about 0.2 mg / kg / day to about 3.5 mg / kg / day administered orally and / or parenterally.

Formulations and uses thereof are provided for supporting human natural defense against viral infections as well as providing treatment for viral infections susceptible to a lysosomotropic agent. Administration of a lysosomotropic agent, such as ammonium chloride (NH4Q), can militate against the uncoating of viruses within the lysosome of an infected cell and thereby minimize infection by viruses whose replication cycle relies upon an uncoating step in such a manner.

Antimicrobial compositions for wound management and methods of producing the same are provided. The present invention relates to an antimicrobial composition comprising sodium hypochlorite (NaOCl) in an amount of from 0.015 wt% to 0.15 wt%, hypochlorous acid (HOCl) in an amount of from 0.002 wt% to 0.1 wt%, a thickener based on synthetic silicate clay in an amount of from 1 wt% to 10 wt%, sodium chloride (NaCl) in an amount of from 0.03 wt% to 0.3 wt%, and purified water, wherein the purified water has a hardness, measured according to ISO 15923-2: 2017, of less than 5 ppm and a resistivity, measured according to ISO 3696: 1987, of greater than 15 M [omega] / cm before being added to the composition, and wherein the pH of the composition is in the range of 7.5 to 10.0, and wherein the buffer capacity [beta], measured at pH 8.0, is 0.15 or less.

The present invention provides new storable and stable disinfectant compositions comprising use of a solid precursor of an oxidized state of chlorine. The component in the device is devoid of stability issues, since the solid precursors are instantly to be dissolved in water or a pharmaceutically acceptable diluent, adjuvant, or carrier, and combined with an activator, e.g. adipic or succinic acid or their salts, optionally combined with a viscosity enhancer, optionally combined with a dye. The main product according to the invention is generated by dissolving effervescent material in the form of tablets or granules, the resulting solutions from dissolution of the effervescent material are useful disinfectants for treating a broad spectrum of pathogenic bacterial and / or viral, fungal, or parasitic pathogens, denoted microbials.

The present invention concerns materials and methods for treating an ocular Demodex mite infestation of an eye of a human or animal subject, or for treating a condition of the eye or skin associated with ocular Demodex mite infestation, the method comprising topically administering a composition comprising one or more spinosyn compounds to the ocular surface (conjunctiva and / or cornea) or other anatomical structure of the eye, or to an area adjacent the eye.

Described is a method for treating or preventing an infection, such as an infection associated with Staphylococcus epidermidis such as a Health-Care Associated infection, a wound, a sore, an ulcer, a burn. The method includes applying a treatment preparation to a treatment site, the treatment preparation has a first component having a single amino acid, said single amino acid being leucine, and a second component having an active chlorine compound.

Formulations and uses thereof are provided for supporting human natural defense against viral infections as well as providing treatment for viral infections susceptible to a lysosomotropic agent. Administration of a lysosomotropic agent, such as ammonium chloride (NH4Cl), can militate against the uncoating of viruses within the lysosome of an infected cell and thereby minimize infection by viruses whose replication cycle relies upon an uncoating step in such a manner.

Described herein are method and kits for locally treating or preventing infection in a patient in need thereof. The method may include locally administering to a human patient a plurality of doses of at least one antiseptic agent in solution by irrigating the at least one antiseptic agent at a wound, wherein the administration provides the patient continuous localized antiseptic therapy for at least a 24-hour period, at least 48-hour period, at least a 72-hour period, or at least a 96-hour period.

Methods for treating or preventing ulcers caused by Epidermolysis Bullosa (“EB”), EGFR inhibitor-induced skin toxicities, lesions caused by Hailey-Hailey Disease (“HHD”), Buruli Ulcers, and SARS-CoV-2 infections, by topically applying a hypotonic, acid oxidizing solution containing hypochlorous acid (HClO) to the affected area.

A composition for lubricant formulations is disclosed. The composition may include hypochlorite, dimethicone, and an emulsifier for improvement of lubricity. Methods of making and using the lubricant formulations are also disclosed.

The present specification discloses a method of preparing a composition stably comprising one or more peroxides and one or more free available chlorine species, the use of one or more peroxides in the manufacture of a composition stably comprising one or more peroxides and one or more free available chlorine species, and formulated compositions using compositions made according to the methods or uses disclosed herein.

The present invention is directed to oral pharmaceutical compositions comprising at least one statin and at least one antiseptic and / or antibacterial agent. Likewise, it is aimed at their use to prevent and / or treat diseases of the soft tissues present in the oral cavity, such as periodontal disease. A method is also described for preventing and / or treating diseases of the soft and hard tissues surrounding the tooth present in the oral cavity that comprises administering said pharmaceutical composition.

Embodiments may relate to compositions and methods for treating hair loss, which may include treating alopecia. The compositions and methods relate to oral supplements to oral minoxidil, including an SLC22A9 inducer, a HIF-α inducer, and / or an acidifying agent. Acidifying the blood of patients suffering from alopecia can cause mild acidosis, which can upregulate SLC22A9 and / or downregulate AABC3. Induction of SLC22A9, induction of HIF-α, and / or acidifying the patient's blood can facilitate the entry of oral forms of minoxidil into hair follicles.

To provide a new method capable of easily sterilizing spores with high safety.SOLUTION: A radical manufacturing method includes a treatment step of irradiating a radical generating source with light, generating a radical, and treating spores with the radical, wherein a peak wavelength of the irradiation light in the light irradiation exceeds a UV wavelength and is 600 nm or less. A spore sterilization method includes a treatment step of irradiating a radical generating source with light, generating a radical, and treating spores with the radical, wherein a peak wavelength of the irradiation light in the light irradiation exceeds a UV wavelength and is 600 nm or less. The peak wavelength is, for example, 405 to 470 nm.SELECTED DRAWING: None

The present specification discloses a composition comprising, consisting essentially of, or consisting of hypochlorous acid or free available chlorine in combination with one or more quaternary compounds or silicon quaternary compounds, one or more guanide-containing compounds, one or more alcohols, one or more metallic particles, one or more metal salts, or any combination thereof. The present specification further discloses a kit comprising, consisting essentially of, or consisting of a one or more containers including a composition disclosed herein or components which make up such compositions as well as methods and uses for such compositions and kits.